![](/File_Path/2013_12/images/Techpool.jpg)
The introduction of the exclusive distribution right of the third generation diphosphonate drug for the treatment of osseous metastasis - Ibandronic Acid Injection (brand name: Bondronat®) in mainland China from Roche Group has helped Techpool gain 1% of domestic market.
After the successful cooperation with national big pharma, Techpool has started to negotiate with Japanese pharmaceutical companies Takeda on the introduction of severe disease and cancer related medication.
![](/File_Path/2013_12/images/takeda-pharmaceutical-co.gif)
Techpool is the global leader in urinary protein biopharmaceuticals which specializes in the sales, R&D and production of biopharmaceuticals in critical care. It is expected that Techpool shall have revenue between RMB 2billion to 4billion in 2016 and become the top 5 global bio-pharma companies.